학술논문
Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma
Document Type
article
Author
Source
Journal of Bone Oncology, Vol 29, Iss , Pp 100364- (2021)
Subject
Language
English
ISSN
2212-1374
Abstract
More than 35% of lung adenocarcinoma patients have bone metastases at diagnosis and have a poor survival. Periostin, a carboxylated matrix protein, mediates lung cancer cell dissemination by promoting epithelial-mesenchymal transition, and is involved in bone response to mechanical stress and bone formation regulation. This suggests that periostin may be used as a biomarker to predict survival in lung cancer patients.Serum periostin was assessed at diagnosis in a prospective cohort of 133 patients with lung adenocarcinoma of all stages. Patients were divided into localized and bone metastatic groups. Both groups were matched to healthy controls. Survival analysis and Cox proportional hazards models were conducted in the total population and in bone metastatic group.The median serum periostin level was higher in bone metastatic (n = 67; median: 1752 pmol/L) than in the localized group (n = 66; 861 pmol/L; p median) had a poorer overall survival in the whole population (33.3 weeks vs. NR; p